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Abstract
The resources invested in research do not guarantee an immediate practical application. Companies and government increasingly seek mechanisms
for prioritizing R&D projects appropriately when resources are insufficient. This study’s objective was to develop and present a methodology
used to evaluate the portfolio of research and help choosing the best investments in research. This methodology was applied at the Butanta
Institute, in Brazil, an organization responsible for researching and developing, among other medicines, vaccines and other chemicals, Onco BCG,
a medication for the treatment of bladder cancer. In the article, we present and analyze the methodology used at Butanta Institute. Conclusions
show that literature on R&D portfolio management advises the use of risk and return criteria, when choosing among projects. In the case study of
Butanta, the methodology of choice was based more on the customer’s perspective.
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Introduction
Choosing the best portfolio of projects of research and devel-
opment (R&D) is an important discussion when dealing with
technological strategy. One reason for that is the substantial
amount of investment on research and which not always can be
reflected into results. Another issue is the cash flow dilemma:
expenses in research and development today can bring results
in a long term perspective. This paper presents a methodology
for evaluation of the R&D portfolio at a government institute,
in Brazil, which is responsible for development of many medi-
cations.
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Decisions regarding investment in R&D generated a line of
studies under technological strategy, named portfolio selection
process (Blanes i Vidal & Möller, 2016). In this field, past studies
have come up with methodologies that support decision mak-
ers in choosing how they will invest their financial resources,
given the amplitude of R&D projects available. Many of these
methods are built on complex methods such as the fuzzy logic
(Bhattacharyya, 2015). However, these methods do not fit all
types of companies or the problems they face; one of these cases
where there is a call for more adaptive models is the case of
nonprofit organizations (Jeng & Huang, 2015).
One of the nonprofit sectors that demand such studies is the
Health Programs, as the results of the research directly impacts
the population well-being. Avoiding primary research can pre-
vent the discovery of cure for many diseases.
When we look for answers for the problem of choosing
the best R&D portfolio of projects, part of the literature show
methodologies of evaluation of R&D portfolio based on the
trade-off between risk and return. Those studies consider the
financial impacts as the most important criteria for decision.
This fact is expected, considering that the most part of the studies
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focus on private companies. When it comes to health develop-
ments, the search of the cure of important diseases depends on
projects that have high costs and also high risks. In the trade-off
between risk and return, used as the only criteria for the selection,
these projects could be among the least preferable ones. This is
specifically true for the case of non-governmental organizations
(Lacerda, 2015). The choice of less risky projects could make
impossible the cure of important diseases, in the future.
This study objectives to develop and apply a methodology
for choosing the best portfolio of R&D when it comes to the
development of one of the products of Butanta Institute: the Onco
BCG vaccine. This vaccine is one of the medications designed
for the treatment of bladder cancer.
Butanta Institute is a governmental agency affiliated with the
Sao Paulo State Health Department, in Brazil. It carries out many
activities aimed at preventing and correcting health problems
faced by the population of the state. Among these activities,
there are scientific and technological research projects devel-
oped by state-owned research institutions. Such research is very
frequently out of touch with the Department of Health’s priority
needs. This happens partly for lack of awareness of the Depart-
ment’s needs, which are not taken into consideration. There
are evidently other reasons for the mismatch. Martin (1994)
highlights the importance of investing in innovations geared to
clearly identified needs so as to increase the chances of success.
Although his observation relates to private-sector companies, it
is equally applicable to the public sector. Another possible rea-
son for the divergence between strategic research needs and the
research that is really developed is that, in the Butanta Institute
case, the research is primarily funded and developed by scien-
tists with academic scholarships provided by the government;
given that, the ones who decide what subject will be researched
are the scientists themselves, according to their own research
interests. The demand for research comes not necessarily from
the Butanta Institute or its product engineers, but it comes from
the researchers themselves.
The study described here entailed the development of a
methodology for evaluating R&D project portfolios and partial
application to test its effectiveness. The experiment demon-
strated the method’s considerable potential as an ancillary
instrument for evaluating an R&D portfolio. To test the method-
ology we chose BCG immunotherapy, a medication used in the
treatment of bladder cancer. If these needs are identified, part
of the research effort can be directed toward supporting them so
as to increase the general public’s satisfaction with the health
services provided by the public sector, at a lower cost to society.
Conceptual framework
Procedures to manage portfolios of technology projects have
been developed and applied by private enterprise as part of a
broader process known as Technology Management. The pur-
pose of Technology Management is to ensure that technology is
used to leverage competitiveness by creating new products and
processes, enhancing existing ones, cutting costs, and devel-
oping patents that guarantee a temporary monopoly. Among
the tools of Technology Management is Strategic Technology
Planning, which comprises several stages including project
portfolio management. These concepts can also be used by
public-sector entities. In this case the pursuit of profit is replaced
by the desire to create quality products and services for society
at a low cost and on a timely basis. Once priority needs have
been identified, the existing project portfolio can be evaluated
and new projects identified. Existing project selection methods
can then be applied.
Technology is an ancillary instrument for the implementa-
tion of such programs. It boosts their performance in terms
of quality and cost savings, so that healthcare services can be
extended to more people for the same cost. Hence the importance
of establishing R&D priorities.
It must be stressed out, however, that part of the resources
allocated to research should be kept available for projects geared
to the advancement of science. This is especially valid for gov-
ernmental research institutions, although some private-sector
firms invest a small proportion of available funds in scientific
research.
Context of project portfolio decisions
Project portfolio management should be aligned with the
organization’s technology strategy, which in turn needs to be
integrated with corporate strategy. Much of the specialist liter-
ature on strategic management indicates that one of the main
reasons for which firms develop a strategic plan is the need to
identify the future environment in which the firm intends to oper-
ate. This is done by analyzing a series of variables in order to
establish basic guidelines to be followed by all members with
a minimum of stability. There are many strategy concepts and
typologies, each one advocated by authors who follow one of
the many schools of thought on the subject that have emerged
so far. This paper focuses on the approaches considered most
relevant to the object of study.
On the method of strategy formulation, Mintzberg (1998)
classifies strategies into: emerging strategies, deliberate strate-
gies, and deliberately emerging strategies. For him strategies
can either take shape or be formulated. A given strategy may
emerge as a response to an evolving situation or be introduced
deliberately through a process of formulation followed by imple-
mentation (Oliveira, Salazar, Crêspo, Costa, & Kovacs, 2015).
Thus strategies are termed deliberate when constant planning
intentions have been fully satisfied. Emerging strategies, on the
other hand, derive from actions undertaken by the firm but not
explicitly planned as such.
Because emerging strategies are comparatively flexible, they
stimulate learning but hamper control, since actions are taken
one at a time as the need arises. This type of strategy seems
most suited to situations of technological paradigm change, in
which a “window of opportunity” must be used quickly to estab-
lish a competitive advantage (which also may or may not last).
Deliberate strategies, on the other hand, are intended to establish
the best form of control but cannot accurately foresee the future
and keep all the factors involved within expecting situations so
as to achieve their goals (Neis & Pereira, 2016). As a trade-
off between the two types of strategies Mintzberg proposes a
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deliberately emerging strategy, also known as process strategy.
In this case, “management controls the strategy formulation pro-
cess – focusing on designing structure, staffing, procedures and
so on – but leaves content proper to others”.
In the specific case of technological innovation, Roussel,
Saad, and Erickson (1991) stress the importance of integrating
technology needs identification with corporate strategy. Apply-
ing this concept to the government sector, the Department of
Health should clearly define its strategic priorities in terms of
what products and services to make available to what segments
of the population. The relationship between strategy and tech-
nology management is discussed in depth by Brockhoff (1998).
Bignetti (2001) cites Ansoff (1965) and Andrews (1971) to
argue that classic studies of innovation generally refer to orga-
nizations which interact with relatively stable environments and
are characterized by relatively long product and technology life-
cycles. This is the case, for example, for firms in traditional
industries not significantly affected by technological revolu-
tions or new market preferences. Environmental uncertainty is
reduced because results and demand are reasonably foreseeable.
In such circumstances the actors tend to behave in accordance
with a more deterministic view of the environment. The strategy
prescribed is one of adapting the organization to environmental
threats.
Technological progress can often be seen as deriving from
the competition among technology regimes, design configura-
tions or different options for a design common to a large number
of firms. Mastery of a technology may produce irreversibilities
and constraints: as the technology evolves, future developments
may be tied to a particular paradigm (Dosi, 1982). New techno-
logical discontinuities usually come from outside the paradigm,
from a different industry, or from a new current of knowledge
(Utterback, 1994).
According to Bignetti (2001), from the traditional perspec-
tive technology management has so far evolved through five
generations, from traditional models of technology-push and
market-pull in the 1950s and 1960s to the integrated systems
of the 1990s (Rothwell, 1993, cited by Bignetti, 2001). While
markets, customers and suppliers were gradually inserted into
studies as these generations developed, they are still consid-
ered external sources of information for a fundamentally internal
process of R&D.
Technological competition is described as the result of a
decision-making and social interaction process from which a
technology – not necessarily the best – emerges victorious
(Arthur, 1996). Contrary to expectations based on survival of
the fittest, the final solution may often be an instance of survival
of the boldest. The innovation process is seen not as a sequen-
tial process, from basic research to market, but as a spiral in
which the development of technology is inherently tied to the
implementation stage.
In the sphere of public health it is vital to define a clear and
consistent strategy for action geared to meeting priority health
needs for the different regions and population strata. Technology
is an ancillary instrument in implementing such strategies. There
are various prerequisites for adequate technology use. One of
them, which is the focus for this paper, is to identify priority
technology needs so that it is possible to evaluate how far the
existing R&D project portfolio meets those needs.
Methods of project portfolio evaluation
Project selection is one of the various aspects of R&D project
portfolio management. In this matter, there are many differ-
ent methods that could be used for deciding which is the best
research portfolio. Many of these tools have been based on
fuzzy sets (Pérez, Caballero, Carazo, Gómez, & Liern, 2015)
or complex methods based heavily on data and analysis, using
techniques such as the analytic hierarchy process or linear pro-
gramming (Parvaneh & El-Sayegh, 2016). Recent studies have,
however, challenged researchers to offer methods that adapt to
different types of companies and the problems they face (de
Oliveira Filho, Silveira, & Ana, 2014). Also, they point to the
importance of considering other variables beyond the financial
aspects, such as sustainability (Brook & Pagnanelli, 2014).
An analysis of the types of R&D project portfolio selection
tools showed four main categories, that we describe as follows.
1) Risk evaluation
This type of method is based on decision trees and other
financial methodologies to evaluate the tradeoff between
risk and return, considering the R&D portfolio. Accord-
ing to Brook and Brewster (1999), developing and using a
Customer Needs Tree is a simple and effective way of solv-
ing the problem, with specific benefits in idea generation,
technology assessment, portfolio management and internal
communication.
2) Portfolio grid
The portfolio grid distributes R&D projects according to
their probability of technical success and potential commer-
cial value given success. Matheson and Menke (1994) adopt
this approach, and classify projects in quadrants: bread and
butter (projects with low technical difficulty and low market-
ing potential), white elephant (projects with high technical
difficulty and low marketing potential), Oister (projects with
high technical difficulty and high marketing potential) and
pearl (projects with high potential for commercialization and
low technical difficulty). Jolly (2002) also developed a model
comprising two basic variables: technological competitive-
ness and technological attractiveness. Each can be measured
by 16 factors.
3) Mixed methods
It is common to adopt mixed methods, e.g., the ones based
on financial analysis, that also classify projects on the port-
folio matrix. Tritle, Scriven, and Fusfeld (2000) adopt a
periodical review of the existing projects, followed by project
portfolio graphs, metrics and decision trees.
4) Value added systems
Some authors use a more targeted approach to customer
needs than the previously shown methods. In private insti-
tutions, this may be related to the potential market for the
product. In government institutions, the system lists the best
projects through its potential contribution to society. Linton,
Walsh, and Morabito (2002) use a decision model with more
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Table 1
Authors and categories of methodologies they have used.
Categories Authors
Value creation Linton et al. (2002)
Portfolio matrix Matheson and Menke (1994)
Mixed systems Tritle et al. (2000); Lint and Pennings (2001)
Trade-off risk × return Graves, Ringuest, and Case (2000); Rzasa et al.
(1990); Morris et al. (1991); Brook and Brewster
(1999); Ringuest and Graves (2005); Kolisch,
Meyer, and Mohr (2005)
Source: Authors.
than one criterion, and chooses the priority projects that cre-
ate higher value for the consumer.
Table 1 synthesizes these types of methods for evaluation of
R&D projects as explained before.
Following the last approach in Table 1– trade-off risk × return
– Osawa and Murakami (2002) developed and applied a two-
stage methodology for evaluating R&D projects in industry. The
first stage comprises the development of the evaluation platform
in three steps:
a) Philosophy: Identifies what lies behind the decision, based on
information from the firm’s business plan, strategies, vision
and mission. Two types of criteria are defined: qualitative
criteria to evaluate the suitability of a project in terms of the
extent to which it matches the firm’s strategy; and quantitative
criteria relating to financial aspects, among others.
b) Outline of five criteria: (1) strategic importance and tech-
nological effect; (2) probability of realization; (3) sales; (4)
profit and (5) R&D efficiency.
c) Outline of evaluation platform, comprising an analysis of
three factors: Input, calculation, and output.
The second stage deals with utilization of the evaluation plat-
form, as summarized in Fig. 1.
Chien (2002) presents a framework for evaluating alternative
portfolios of R&D projects. The basis for his study is the need
to evaluate inter-relations among projects. A set of very good
projects is not necessarily best for the firm because relations
among projects entail additional synergies not considered by
the traditional method.
Evaluation of a portfolio of R&D projects should take account
of technology needs. Technology needs identification should
take place simultaneously along two main avenues. The first
involves evaluating the production processes used for a product
or service, and detecting any potential for enhancements that
could give rise to research projects (Vasconcellos, 1990). The
second consists of evaluating the scientific and technological
trends that could completely eliminate a disease or drastically
alter production techniques, such as the advances derived from
molecular biology and genetic engineering. S-shaped curves
and the concepts of disruptive technologies and technological
obsolescence are discussed in depth by Sanderson and Uzumeri
(1997), Christensen (1997), and Sahal (1991). Although this
paper focuses on the first avenue outlined above, any technology
needs identification process should include both avenues.
Recommendations for the evaluation of R&D portfolios
Considering the recommendations and best practices to the
evaluation of R&D portfolio, to Hodder and Riggs (1985), the
choice of R&D projects requires consideration of the risk of three
distinct project phases: research, product development and sales.
Matheson and Menke (1994) complement this advice with the
idea that the selection should not focus on evaluation of the indi-
vidual projects; to maximize one’s return, there is need to make
quality decisions at the portfolio level mixing high risk – high
potential R&D with lower-risk projects that produce near-term
returns through incremental improvements to existing products
and processes.
Morris, Teisberg, and Kolbe (1991) criticize the use of
methodologies based on the analysis of risk and return only. For
them, this type of methodology can lead the manager to avoid
dealing with the riskier projects. However, they understand that
if two projects have the same expected payoffs and the same
costs, but different risks, and different ranges of possible out-
comes, a conscientious R&D manager should choose the riskier
one. The authors also point that this decision is better even for
risk-averse managers. If a manager can choose several projects,
than he can benefit from having a portfolio of risk projects. This
happens because a project with more downsized risk has a higher
Input data to
evaluation
platform
Discuss
within each
laboratory
Discussion
between lab &
corporate dev.
dept.
Modify
input to
evaluation
platform
Evaluation
results posted
on intranet
Budget planning of R&D group
Step 2 Step 3 Step 4Step 1
Fig. 1. New methodology using evaluation platform.
Source: Osawa and Murakami (2002).
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expected value in the commercial phase and this higher value
outweighs the lower chance of success in the research phase.
Cooper, Edgett, and Kleinschmidt (1998) present the results
of a survey in which financial methods were rated as having more
weaknesses than strengths. For them, a good project follows
six criteria: portfolios are aligned with the business objectives,
contains very-high-value projects, reflect the business strategy,
are done on time – no gridlock, have good balance of projects
and finally they have the right number of projects.
Tritle et al. (2000) consider that the R&D portfolio must
be in balance with corporate goals and strategies – neverthe-
less, assessment of qualitative information is critical. Kirchhoff,
Merges, and Morabito (2001) also consider, based on their expe-
rience on Lucent Technologies Lab, that the value creation is
better than focusing only on financial aspects.
Finally, Rzasa, Faulkner, and Sousa (1990) suggest that it is
important to internalize the methodology at the group level and
then internalize it at the business unit level.
In this study, we present a framework for R&D project eval-
uation that was not based on fuzzy sets, but instead considers
the specific demands for a non-governmental agency.
Methods
As seen before, this study’s objective is to present and analyze
the case of Butanta Institute and its methodology for choosing
the best portfolio of R&D when it comes to the development of
one of its products: the Onco BCG vaccine.
This study presents the results of a practitioner work devel-
oped in Butanta Institute. Therefore, this paper is the result of
an action research methodology.
To achieve this goal, the practitioner project was developed
in 6 steps, described as follows.
1) First block of interviews: First, those responsible for the
Butanta Institute, in order to collect information about the
strategic direction of the organization were interviewed. This
first block lasted for interviewing 4 h.
2) Second block of interviews: In sequence, respondents were
mainly responsible for the BCG Onco product. This second
set of interviews lasted 30 h and was conducted over several
sessions. The purpose of interviews was with much depth
to determine what are the surveys that were proposed to the
institute and that would be viable for achievement. Thus, the
aim of delineating which initial portfolio of research which
is being treated. It is important to remember that, unlike what
happens in private institutions, which often need to make use
of creativity techniques to raise ideas for research to be con-
ducted in the case of Butanta Institute these ideas have been
proposed by researchers, presenting research projects that
may or may not be funded by government agencies. These
30 h of interviews were aimed at collecting information about
requests of previous studies and identify any needs that have
not been proposed by researchers to date.
3) Third block of interviews: In the third block, were made with
the main panels that serve the users of BCG Onco product.
This block was designed to assess the factors critical to the
success of BCG Onco from the viewpoint of its users. It
is important to note that doctors who prescribe the drug the
best people to provide information about their improvements
and critical success factors, although users of BCG Onco are
patients who are treated with this medication are. So were
collected from people dealing with doctors.
4) Development of methodology to be used by the institute.
Based on the information collected, broke for the elaboration
of the method for selecting the portfolio of research at the
institute. This method is described as follows, between the
results obtained.
5) Application of the methodology for selecting the portfolio
of research and data analysis. In this fifth step, we applied
this methodology to the case of BCG Onco and sought to
identify the research that have high potential alignment with
the strategy of the institute and improvements to BCG Onco
product based on the critical success factors raised in the
third step.
6) Assessment methodology: The end of the application of the
methodology, were conducted more interviews with those
responsible for the BCG Onco order to verify the applicabil-
ity of the methodology used.
Butanta Institute
Butanta Institute was founded in February 1901 to combat an
outbreak of bubonic fever in the port city of Santos, in Brazil,
and it has since become a center for research and production of
antivenom sera. The institute currently focuses on the develop-
ment of high social impact biopharmaceuticals:
• Erythropoietin: Erythropoietin cloning and purification are
under development by the institute for use by more than
25,000 kidney patients who are awaiting transplants and cur-
rently cost the health system some 50 million US dollars.
• Lung surfactant: An industrial plant is under development for
production of 500,000 doses of lung surfactant per year, to be
used primarily in premature babies with immature lung syn-
drome due to insufficient time in the womb for lung formation.
Another application is in adult patients with lung problems.
• Anti-CD3: Anti-CD3 is under production to meet interna-
tional demand as well as for distribution in the domestic
market. It is used to constrain thrombus progression and as a
topical anticoagulant.
In recent years Butanta Institute has stood out as the lead-
ing research institution in Sao Paulo State based on the number
of indexed publications, similar to that of the main institutions
belonging to the University of Sao Paulo, with which it collabo-
rates in graduate programs for master’s and doctoral degrees in
biology and biotechnology.
Application of portfolio evaluation method
The method proposed in this paper for evaluating a portfolio
of R&D projects comprises five stages, as shown in Fig. 2.
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Strategic guidelines
Design of the evaluation matrix
• Identification and weighting of performance factors
• Study of production process and identification of production stages
Product selection
Completion of matrix
• Performance factors vs. stage of production
• Identification of technolgy needs covered by projects in progress
Proposals of new projects
• Technology gaps 
• Technology trends
Fig. 2. Method for R&D project portfolio evaluation and improvement.
Source: Butanta Institute, research data.
As shown in Fig. 2, the method was applied to a single prod-
uct in order to test the procedure. Thus only portfolio projects
relating to the selected product were evaluated. The procedure
should be applied to all products of Butanta Institute, generating
a large number of projects for selection using existing methods.
Project interdependency should be taken into consideration dur-
ing this stage (Oullet & Martel, 1995; Ringuest, Graves, & Case,
1999).
The analysis of the project portfolio for Onco BCG comprised
the steps set out as follows, in accordance with the stages of the
proposed methodology.
Strategic guidelines
A meeting with the Technical Committee enabled the main
strategic guidelines of Butanta Institute to be identified. We also
identified its main areas of activity and the segments of the
community served by the institute.
Product selection
The next step involved an initial meeting with the institute’s
coordinators followed by meetings with those responsible for
the potential products to be used in the study, as identified in
the previous step. It was then possible to decide which product
would be studied, taking into consideration factors such as the
relevance of the product to the overall strategy of the institute.
The product chosen in this case was BCG immunotherapy, also
known as Onco BCG, currently used in the treatment of bladder
cancer.
Design of evaluation matrix
This stage comprised two parts: identification and weighting
of performance factors, and study of the production process to
identify production stages.
Identification and weighting of performance factors: This
step consisted of meetings with those responsible for manufac-
turing the chosen product to determine the performance factors
customers expect from the product and the relative weight of
each factor. These performance factors can be understood as
key features to ensure that the customer’s problem is resolved
with quality and at low cost. Customers are defined not only
as patients who receive the products for treatment but also as
physicians who prescribe it and professionals responsible for
application, such as nurses and once again physicians.
Performance factors for Onco BCG are as follows:
• Longer shelf life – The longer the shelf life, the longer the
product can be stored, meaning less waste and better control
by the nurses and physicians who use it. In addition, a product
that can be stored longer is more easily distributed to distant
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regions or locations that use it on a smaller scale. The latter
can receive annual shipments of the product, for example.
• Lower cost – Lower cost allows for production of larger quan-
tities and thus coverage of an even larger segment of the
population in need of the product.
• Less side effects – Side effects are undesirable consequences
of treatment with medication. Less side effects mean better
quality treatment and more patient satisfaction.
• Immunogenicity – Immunogenicity is the patient’s response
to the medication. A high degree of immunogenicity indi-
cates that the product is doing its job and that treatment is
proceeding satisfactorily.
• Ease of application – The product should be easy and conve-
nient to apply. This means, for example, rapid reconstitution
and no need for an arsenal of equipment for administering the
product.
• Resistance to temperature variation – The medication needs
to be stored, transported and handled under differing condi-
tions in terms of temperature and the general environment.
It should be formulated and packaged in such a way as to
withstand temperature variations and to suit the environment
in which it will be used.
Study of production process and identification of production
stages
Once the performance factors had been determined, the Onco
BCG production process was mapped out. More meetings were
held to discuss details of the production process, divide it into
stages, and diagnose each stage separately. This step of the
methodology included a visit to the production facility, provid-
ing an opportunity to see how Onco BCG is manufactured and
in particular the rigorous care taken at every stage of the pro-
cess. The columns in Chart 4-1 represent the various stages of
production.
Completion of matrix
The matrix produced in the previous step was completed
in two stages: performance factors vs. stages of production;
and identification of technology needs covered by projects in
progress.
Performance factors vs. stages of production: To facilitate the
analysis and as part of the proposed methodology, a matrix was
created (Table 2) correlating the information on performance
factors and production stages. Each cell in which the two vari-
ables intersect is used to show the importance of each production
stage in achieving the performance factors for the end-product.
Each cell is ranked on a scale from 1 to 3. Cells with the
highest potential to have a positive influence on the desired per-
formance are ranked 3. Cells with little or no importance in
terms of potential satisfaction of the performance criteria are
left blank.
As shown in Table 2, identification of technology needs cov-
ered by projects in progress: the matrix presented above was
completed in order to analyze the research projects in progress
at the institute and measure their relevance. Relevance is
Table 3
Performance factors and production stages for each project.
Performance factor Production stage
• Longer shelf life • Lyophilization stabilizers
• Lyophilization
• Colony-forming units (CFU)
• Oxygen takeup
• Heat stability
• Lower cost • Lyophilization stabilizers
• Lyophilization
• Colony-forming units (CFU)
• Oxygen takeup
• Heat stability
• Resistance to temperature variation • Lyophilization
• Heat stability
Source: Research data.
represented in terms of the contribution of each production
stage to achievement of the performance factors defined for the
project. Thus by correlating performance factors with the cor-
responding stages of production it is possible to relate projects
in progress with the product’s performance requirements. It is
important to note that needs identification is necessary but not
sufficient. Scientists tend to resist demands not directly related
to their specialties. A study by Cohen, Duberley, and Mcauley
(1999) involving seven government-funded research institutions
analyzed their need for outsourced research and the impact on
the scientists working there, showing the significance of motiva-
tion to ensure that part of the work done by research institutions
is geared to meeting society’s needs.
For each project a detailed chart similar to the example in
Table 3 was prepared, showing the production stages involved
in the project and the performance factors relating to each stage.
The charts were used to guide completion of the matrix presented
in item 4.7 as follows.
Example: Project 1 (P1) – production of freeze-dried BCG
vaccine by sealing under argon
Objective: Implement the use of argon 5.0 (99.999% purity)
for lyophilizer vacuum breaks after bulk lyophilization of BCG
vaccine, thus assuring maximum product stability and rigorous
control of residual moisture.
Proposals for new projects
This step of the methodology has two phases – technology
gaps and technology trends.
Technology gaps: This phase of the study is designed to
analyze the matrix completed in the preceding step, identify
technology needs not covered by the existing project portfolio,
and generate new project proposals.
Table 4 which is based on the matrix presented in Table 3,
shows the analysis performed to determine new technology
needs. Projects already in progress at the time this methodol-
ogy was introduced are represented by numbers (P1, P2, . . .,
Pn). Inclusion of an asterisk (P*1, P*2, . . ., P*n) indicates
projects created in accordance with needs identified using the
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methodology. Triangles highlight significant correlations not
covered by existing research and development projects. If the
methodology was applied in its complete form, databases on
projects in progress at the various research institutions linked to
Butanta Institute would also be queried.
Technology trends: The analysis performed to date needs to
be supplemented by a second avenue of approach focusing on
the trends in technology and science that could make the current
production process used in manufacturing Onco BCG totally
obsolete or unnecessary, owing for example to the introduction
of other treatments that completely cure the diseases treated by
Onco BCG. Examples of such trends in the case of Onco BCG
include:
• Research on recombinant BCG, using molecular biology to
express proteins from other microorganisms that induce an
immune response and afford protection against various dis-
eases.
• Research on recombinant BCG with altered production of
mycobacterial proteins, which could be tested in the treatment
of bladder cancer.
• Research on recombinant BCG producing proteins that mod-
ulate the immune system in cancer treatment.
• Research on fermentation routes to substitute cultivation in
glass vials.
Closing remarks
This study aimed to develop and present a methodology for
selecting the portfolio of research and development (R&D). The
methodology presented was developed within the Butanta Insti-
tute, one connected with the Health Department of the State of
Sao Paulo organization.
First, we sought to analyze the literature on the selection of
research projects and development. The literature review showed
that the authors address this question from four major perspec-
tives. The first is composed of items that leave the concept of
creating value to determine what the best investments in research
and development. A second category of articles is worth the
portfolio matrix techniques, we classify queries that may be
developed along two axes of the matrix. There is also, in a
third category, mixed systems, which draw on the concept of
value creation and portfolio matrices. However, it is a signifi-
cant number of authors in the fourth category – methods that
use the concepts of risk and return for selecting the portfolio of
research to be developed.
The method shown in this paper has some peculiarities in
regard to previous studies. Much of the literature on R&D eval-
uation is based on complex mathematical tools and focuses on
financial aspects, characteristics that are not appropriate for non-
profit organizations (Schaeffer & Cruz-Reyes, 2016) – which is
the case of Instituto Butanta. To adapt to this kind of organiza-
tion, the proposed method has two main characteristics.
First, it considers the opinion of the group who is responsi-
ble for taking decisions. This has been previously pointed by
Lee and Kim (2000) as necessary when the projects evaluated
have possible impacts for society. Additionally, as in the case of
Instituto Butanta, when projects are managed by a group of indi-
viduals, it is necessary to consider the group members’ opinions
when deciding which project to invest.
Second, it takes into account the opinions of experts when
judging the potential value of the projects. According to Liu,
Wang, Ma, and Sun (2016), it is more adequate than financial
measures when the projects’ potential gains are not necessarily
monetary, but instead subjective or parts of larger technological
discoveries.
This analysis of the literature showed that most of the theo-
ries that apply to private organizations can be applied in public
organizations, in particular as regards the issue of improvements
in health. However, the concepts of risk and return, when treated
from a financial perspective, become not ideal tools for this sit-
uation, since the investments in research in the area of health are
often risky, and managers cannot judge the best investment for
those who bring minor scratches. For example, riskier research
can often those related to large and significant improvements,
such as curing major diseases.
Based on this literature, we developed and applied a method-
ology for the selection of research at the Butanta Institute. It was
based on a substantial number of hours of interviews to obtain
data that provided the basis for the study.
The results showed, first, that the selection of the portfolio
of research should first be based on the strategic direction of
the institution. Another assumption that is made is based on
customers’ perceptions of the product studied – the BCG Onco
– about which requirements should be prioritized when it sought
to improve the product – what are the critical success factors.
The methodology and its evaluation by the responsible in the
Butanta Institute, showed that this method was easy to apply and
use, may be used by the institution for the selection of research
to be conducted.
Based on the results, we conclude that, although the tech-
niques are based on risk and financial return are of higher value,
researchers and R&D managers must consider the strategic and
client perspectives when selecting the best portfolio of research.
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